Drug
WR 279,396
WR 279,396 is a pharmaceutical drug with 5 clinical trials. Historical success rate of 80.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
80.0%
Based on 4 completed trials
Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
75%(3 trials)
Terminated
1(20%)
Phase Distribution
Ph not_applicable
1
20%
Ph phase_3
1
20%
Ph phase_2
3
60%
Phase Distribution
0
Early Stage
3
Mid Stage
1
Late Stage
Phase Distribution5 total trials
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
1(20.0%)
N/ANon-phased studies
1(20.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
80.0%
4 of 5 finished
Non-Completion Rate
20.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(4)
Terminated(1)
Detailed Status
Completed4
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
80.0%
Most Advanced
Phase 3
Trials by Phase
Phase 23 (60.0%)
Phase 31 (20.0%)
N/A1 (20.0%)
Trials by Status
completed480%
terminated120%
Recent Activity
0 active trials
Showing 5 of 5
terminatedphase_2
Safety, Efficacy, and PK of Topical Paromomycin/Gentamicin Cream for Treatment of Cutaneous Leishmaniasis
NCT01140191
completedphase_3
Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama
NCT01790659
completedphase_2
Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World
NCT00703924
completedphase_2
WR 279,396 for the Treatment of Cutaneous Leishmaniasis
NCT01988909
completednot_applicable
Cosmetic Outcome of Leishmaniasis Scar After WR279396 Application
NCT00490230
Clinical Trials (5)
Showing 5 of 5 trials
NCT01140191Phase 2
Safety, Efficacy, and PK of Topical Paromomycin/Gentamicin Cream for Treatment of Cutaneous Leishmaniasis
NCT01790659Phase 3
Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama
NCT00703924Phase 2
Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World
NCT01988909Phase 2
WR 279,396 for the Treatment of Cutaneous Leishmaniasis
NCT00490230Not Applicable
Cosmetic Outcome of Leishmaniasis Scar After WR279396 Application
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5